SB 11285 + atezolizumab

SB 11285 + atezolizumab is an investigational **combination therapy** comprised of SB 11285—a second-generation STING (Stimulator of Interferon Genes) agonist—and atezolizumab, an anti-PD-L1 monoclonal antibody checkpoint inhibitor. SB 11285 is a small molecule–nucleic acid hybrid designed to activate the STING pathway, boosting type I interferon production and stimulating immune cell infiltration by engaging the innate and adaptive immune responses. Atezolizumab blocks the PD-L1 protein on tumor cells to prevent immune evasion, allowing T-cell activation and tumor targeting. Combined, SB 11285 enhances immune system activation, potentially increasing the efficacy of atezolizumab against solid tumors otherwise resistant to checkpoint inhibitors. Trials are focused on patients with advanced or metastatic solid tumors, including a broad range of cancer types. SB 11285 was developed by Spring Bank Pharmaceuticals, later acquired by F-star Therapeutics, with clinical trial sponsorship also involving invoX Pharma Limited and Sino Biopharm[1][2][3].

Other names

SB 11285 + atezolizumabanti-PD-L1 + STING agonist